Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 20 September 2017, 12:57 HKT/SGT
Share:
    

Source: Sisram Medical Ltd
Net Proceeds of approximately HK$877.2 Million from Global Offering; Sisram Med Trading Debut on SEHK on 19 September 2017

HONG KONG, Sept 20, 2017 - (ACN Newswire) - Sisram Medical Ltd ("Sisram Med" or the "Company"; stock code: 1696.HK), announced the allotment results of its global offering, which offers a total of 110,000,000 shares comprising of 88,000,000 new shares offered by the Company and 22,000,000 sale shares by a controlling shareholder, Magnificent View Investments Limited (the "Selling Shareholder"). The offer price was set at HK$8.88 per share. Assuming that the over-allotment option is not exercised, the net proceeds from the global offering to be received by the Company, after deduction of underwriting fees and commissions and estimated expenses payable in connection with the global offering, are estimated to be approximately HK$688.7 million; while those to be received by the Selling Shareholder, after deduction of underwriting fees and commissions payable, are estimated to be approximately HK$188.5 million.

The valid applications received pursuant to the Hong Kong public offering represented approximately 17.58 times of the total number of 11,000,000 Hong Kong offer shares initially available for subscription. Due to the over-subscription, a total number of 22,000,000 shares have been reallocated from the international offering to the Hong Kong public offering. As a result, a final number of 33,000,000 offer shares were allocated to the Hong Kong public offering, representing 30% of the global offering size before any exercise of the over-allotment option.

The international offering was also moderately over-subscribed. After reallocation, a final number of 77,000,000 offer shares were allocated to the placees and qualifying shareholders of Fosun International Limited under international offering, including the reserved shares offered under the preferential offering.

Sisram Med has entered into cornerstone investment agreements with Shanghai Free Trade Zone Phase I Equity Investment Fund Partnership Enterprise (Limited Partnership), Rise Huge Corporation Limited and Neo Derm Group Limited for the subscription of aggregate 25,296,800 offer shares, with respective offer shares of 13,175,600 shares, 8,783,600 shares and 3,337,600 shares, accounting for approximately 23.00% of the global offering size before any exercise of the over-allotment option.

China International Capital Corporation Hong Kong Securities Limited ("CICC") and Jefferies Hong Kong Limited (in alphabetical order) are the joint sponsors, and together with Fosun Hani Securities Limited are the joint global coordinators. The joint global coordinators, together with Haitong International Securities Company Limited, Huatai Financial Holdings (Hong Kong) Limited and CMB International Capital Limited (in relation to the international offering only) are the joint bookrunners and joint lead managers. CICC is the sole settlement agent and sole stabilizing manager.

Share trading of Sisram Med on the Main Board of the Hong Kong Stock Exchange Limited ("SEHK") was commenced on 19 September 2017 (Tuesday), with the stock code 1696 in board lots of 400 shares each.

About Sisram Medical Ltd
Sisram Medical Ltd (stock code: 1696.HK) is a leading global provider of energy-based medical aesthetic treatment systems, with comprehensive in-house capability to design, develop and produce such systems, which often feature the Company's innovative and proprietary technologies. "Alma" brand, as well as the brands of many of the Company's products such as "Soprano", "Harmony", "Accent" and "FemiLift", are widely recognized and well regarded among treatment providers and treatment recipients internationally. The Company has also been the largest provider of energy-based medical aesthetic treatment systems in the PRC market and one of the leaders in the medical aesthetic treatment system market globally, in terms of revenue in 2016, according to the Medical Insight Report. The company sells its treatment systems in approximately 80 countries and jurisdictions worldwide. Sisram Med, incorporated in 2013 in Israel, is a non-wholly owned subsidiary of Fosun Pharma. Fosun Pharma is a leading healthcare group in China with businesses covering the whole healthcare industry chain.



Sept 20, 2017 12:57 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Sisram Medical Ltd
Dec 6, 2017 16:34 HKT/SGT
The New ALMA BEAUTY SPADEEP Platform Launched Globally After Receiving Outstanding Feedbacks in the Japanese Market
Nov 27, 2017 11:38 HKT/SGT
Sisram Medical Ltd Increase in Shareholding by Controlling Shareholder and CEO As a Vote of Confidence and Trust in the Company's Future Success
Sept 29, 2017 18:31 HKT/SGT
Sisram Med Revenue in First Half 2017 Increased 12.9% to US$66.3 Million
Sept 20, 2017 12:34 HKT/SGT
Sisram Med Successfully Listed on Main Board of SEHK
Sept 5, 2017 17:00 HKT/SGT
Sisram Medical Offers price between HK$8.88 and HK$12.35 per share
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: